Personalized treatment for lung cancer patients with pleural effusion using organoids
Official title: Organoid-guided Personalized Treatment of Pleural Effusion
Run by Henan Cancer Hospital · NCT06959173 · Data updated 2026-11-12
This study is testing whether using lab-grown versions of lung cancer tumors can help doctors choose the best treatment for patients with lung cancer who have fluid buildup in their lungs.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Henan Cancer Hospital Government |
| Locations | 1 site (Zhengzhou, Henan) |
| Status | Recruiting |
| Started | February 21, 2025 |
| Main results expected | January 2027 |
| Study ends | January 2027 |
| Registry record updated | May 6, 2025 |
| Trial ID | NCT06959173 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and above with malignant pleural effusion and an ECOG score of 0-2.
✕Probably not a fit
Patients with a history of malignant tumors in the past 5 years or those with serious complications may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on lung cancer patients suffering from pleural effusion by utilizing patient-derived tumor organoids to predict drug sensitivity. The research involves acquiring clinical samples, culturing organoids in vitro, and conducting drug sensitivity tests to guide treatment decisions. By correlating the sensitivity results with clinical medication guidance, the study aims to enhance treatment plans tailored to individual patient needs. The study is conducted at a single center, Henan Cancer Hospital, with a sample capacity of 20 patients.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and personalized treatment options for lung cancer patients with pleural effusion.
How similar studies have gone: While the use of organoids for drug sensitivity testing is a growing field, this specific approach for lung cancer and pleural effusion is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: (1)18 years of age and above; (2) Understand and voluntarily sign the informed consent form (ICF), and have good compliance, and can cooperate with diagnosis and follow-up; (3)ECOG score 0-2; (4) Accompanied by malignant pleural effusion; Presence of at least one measurable lesion as assessed by the investigator; Exclusion Criteria: 1. A history of malignant tumor in the past 5 years; 2. Complicated with serious complications, such as uncontrolled heart disease, severe arrhythmia requiring medical treatment, persistent watery diarrhea, etc.; 3. Pregnant or lactating female patients; Patients deemed unsuitable for participation in this study.
Where it's running
-
Henan cancer hospital
Zhengzhou, Henan, China Recruiting
Study contacts
- Study coordinator: Qiming Wang
- Email: qimingwang1006@126.com
- Phone: 13783590691
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.